Minerals Technologies

MTX · NYSE

$62.56+$0.24 (+0.39%)TodayMarket closed ·
Prev close $62.32

MTX analyst rating

BuyConsensus of 2 analysts over the last 12 months. 100% rate it a buy.
  • Strong buy0
  • Buy2
  • Hold0
  • Underperform0
  • Sell0

12-month price target · 5 analysts

Average $94.35 (+50.8% upside)

Low
$90.90
Now
$62.56
High
$105.00

Upgrades and downgrades

The latest rating actions, newest first

MTX analyst upgrades, downgrades and rating actions
FirmDateActionRating
Freedom Capital MarketsSep 23, 2026MaintainsBuy
Freedom Capital MarketsSep 18, 2026MaintainsBuy
Truist SecuritiesMay 4, 2026MaintainsBuy
Truist SecuritiesFeb 2, 2026MaintainsBuy
Freedom Capital MarketsNov 21, 2025InitiatesBuy

The case for and against

Updated Oct 18, 2026

Bull case

Minerals Technologies is supported by a differentiated moat built on mineral reserves, engineering capabilities, and technical know-how, which helps sustain stable earnings and dominant positions in core products. Management’s longer-term 2031 targets of about 5% organic growth, 16% operating margins, and free cash flow near 7% of sales, plus a $1.4 billion innovation pipeline and 19% of 2025 revenues from new products, suggest expanding breadth and durability. The outlook is further strengthened by near-term and multi-year catalysts such as growth in cat litter, bleaching earth for sustainable aviation fuel, PFAS remediation, and new opportunities in metals recovery and calcium metal that could add meaningful revenue.

Bear case

  • Minerals Technologies is facing a weaker fundamental backdrop as higher fuel, energy, and logistics costs are pressuring margins faster than pricing can recover, with management citing a $2M operating income headwind in 1Q and a $3M impact in 2Q and pricing lags of up to 90 days.
  • Estimate cuts reinforce that pressure: adjusted EPS is now expected at $1.45 for 3Q versus $1.54 consensus, $5.84 for FY26 versus $5.87 previously, and $6.70 for FY27 versus $7.00 consensus, all while FY25 adjusted EPS was $5.52.
  • The outlook also remains constrained by cyclical exposure to China and India, secular declines in fine and writing paper demand of 1%-3% annually, and acquisition-related execution risk amid muted organic growth.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.